Trial results

Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

NCT06959784 on ClinicalTrials.gov · last registry update 2025-05-07

142 participants. Due to report 31 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Cardiovascular and cerebrovascular event risk score. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ENROLLING_BY_INVITATION

Phase

P4

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

China-Japan Friendship Hospital

Sponsor type

Other

Enrollment

142

Started

2024-01-01

Primary completion

2026-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Cardiovascular and cerebrovascular event risk score

Conditions studied

Diabetes Mellitus · Cardiovascular Diseases · Cerebrovascular Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.